Seres Therapeutics
MCRB
80 hedge funds and large institutions have $237M invested in Seres Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 9 closing their positions.
518% more call options, than puts
Call options by funds: $809K | Put options by funds: $131K
0.02% more ownership
Funds ownership: 3.96% → 3.98% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 85 → 80 (-5)
13% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 31
27% less capital invested
Capital invested by funds: $326M → $237M (-$88.3M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.49M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 4 |
Morgan Stanley
New York
|
+$867K |
| 5 |
VEA
Virtus ETF Advisers
New York
|
+$397K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$3.04M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$2.03M |
| 3 |
Millennium Management
New York
|
-$2.01M |
| 4 |
O
OrbiMed
New York
|
-$1.19M |
| 5 |
JP Morgan Chase
New York
|
-$1.02M |
MCRB Hedge Fund Activity: Q1 2018 in Review
80 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2018, worth a combined $237M — down 27% from $326M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of MCRB and 5 opened new positions — a net loss of 4 holders — while 31 trimmed existing stakes and 27 added.
The largest buyer was ARK Investment Management, adding an estimated $7.49M. The largest seller was Artal Group, exiting entirely with an estimated $3.04M sold.
- 80 institutional investors held Seres Therapeutics (MCRB) as of Q1 2018, down from 85 in Q4 2017.
- Funds reported $237M of Seres Therapeutics stock for Q1 2018, down 27% quarter-over-quarter.
- 5 funds opened new Seres Therapeutics positions in Q1 2018 and 9 closed out, a net change of -4 holders.
- The largest Seres Therapeutics buyer in Q1 2018 was ARK Investment Management, an estimated $7.49M added.
- The largest Seres Therapeutics seller in Q1 2018 was Artal Group, an estimated $3.04M sold.
Based on aggregated 13F filings for Q1 2018.